Cargando…
Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy
Hepatocellular carcinoma (HCC) is the third most frequent cause of tumor-related mortality and there are an estimated approximately 850,000 new cases annually. Most HCC patients are diagnosed at middle or advanced stage, losing the opportunity of surgery. The development of HCC is promoted by accumu...
Autores principales: | Ding, Xiao-Xiao, Zhu, Qing-Ge, Zhang, Shi-Ming, Guan, Lei, Li, Ting, Zhang, Lei, Wang, Shi-Yang, Ren, Wan-Li, Chen, Xue-Mei, Zhao, Jing, Lin, Song, Liu, Zhi-Zhen, Bai, Yan-Xia, He, Bing, Zhang, Hu-Qin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589693/ https://www.ncbi.nlm.nih.gov/pubmed/28903454 http://dx.doi.org/10.18632/oncotarget.18382 |
Ejemplares similares
-
Identifying key regulating miRNAs in hepatocellular carcinomas by an omics’ method
por: He, Bing, et al.
Publicado: (2017) -
Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies
por: Zhu, Qing-Ge, et al.
Publicado: (2017) -
Nanoplasmonic biosensors for precision medicine
por: Xiao, Yiran, et al.
Publicado: (2023) -
Two predictive precision medicine tools for hepatocellular carcinoma
por: Zhang, Zhiqiao, et al.
Publicado: (2019) -
Prognostic value of EGFR and KRAS in resected non-small cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shi-Ming, et al.
Publicado: (2018)